Dual Specificity Protein Kinase TTK Inhibitors Market, by Product Type (BAY 1217389, BOS-172722, CFI-402257, S 81694, and Others), by Application (Non-hematologic Malignancies, Breast Cancer, Prostate Cancer, Pancreatic Ductal Adenocarcinoma, and Others),
Description
Dual Specificity Protein Kinase TTK Inhibitors Market, by Product Type (BAY 1217389, BOS-172722, CFI-402257, S 81694, and Others), by Application (Non-hematologic Malignancies, Breast Cancer, Prostate Cancer, Pancreatic Ductal Adenocarcinoma, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Protein kinases play an important role in the catalytic activity and signaling functional transduction of critical cellular processes. TTK, also called monopolar spindle 1 (Mps1), is a dual specificity kinase that causes the phosphorylation of both tyrosine and serine/threonine residues. It is one of the spindle assembly checkpoint (SAC) that facilitates the alignment of chromosomes on the metaphase plate in mitosis which is associated with the progression of the cell cycle. TTK is essential for the right alignment of all chromosomes, and subsequently, correct attachment to the mitotic spindle. Targeting this kinase may effectively block chromosome segregation during mitosis, and it could be a great invention for cancer therapy.
Market Dynamics
The increased per capita healthcare spending has enhanced research and development activities for the treatment of chronic diseases, which is expected to drive the global dual specificity protein kinase TTK inhibitors market growth over the forecast period. According to the World Bank estimates in 2019, the per capita healthcare expenditure increased significantly in Latin America. The healthcare expenditure in Latin America was around US$ 638 Mn in 2016, which increased to US$ 666 Mn by 2018.
Increasing approvals for product launches by the regulatory bodies is also expected to drive the market growth over the forecast period. For instance, in January 2019, Dacomitinib, a selective and irreversible inhibitor of EGFR by Pfizer Inc., a leading research-based biopharmaceutical company, received approval from the Ministry of Health, Labour and Welfare of Japan for the treatment of EGFR mutation-positive inoperable or recurrent non-small cell lung cancer (NSCLC).
Key features of the study:
This report provides in-depth analysis of the global dual specificity protein kinase TTK inhibitors market, market size (US$ Mn), and the compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dual specificity protein kinase TTK inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bayer AG, Pfizer Inc., Boston Pharmaceuticals, Nerviano Medical Sciences S.R.L (Part of NMS group), and Servier Laboratories
Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dual specificity protein kinase TTK inhibitors market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dual specificity protein kinase TTK inhibitors market
Detailed Segmentation:
Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Product Type:
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Application:
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Region:
North America
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
U.S.
Canada
Latin America
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
GCC
Israel
Rest of Middle East
Africa
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Bayer AG
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Pfizer Inc.
Boston Pharmaceuticals
Nerviano Medical Sciences S.R.L (Part of NMS group)
Servier Laboratories.
“*” marked represents similar segmentation in other categories in the respective section.
Protein kinases play an important role in the catalytic activity and signaling functional transduction of critical cellular processes. TTK, also called monopolar spindle 1 (Mps1), is a dual specificity kinase that causes the phosphorylation of both tyrosine and serine/threonine residues. It is one of the spindle assembly checkpoint (SAC) that facilitates the alignment of chromosomes on the metaphase plate in mitosis which is associated with the progression of the cell cycle. TTK is essential for the right alignment of all chromosomes, and subsequently, correct attachment to the mitotic spindle. Targeting this kinase may effectively block chromosome segregation during mitosis, and it could be a great invention for cancer therapy.
Market Dynamics
The increased per capita healthcare spending has enhanced research and development activities for the treatment of chronic diseases, which is expected to drive the global dual specificity protein kinase TTK inhibitors market growth over the forecast period. According to the World Bank estimates in 2019, the per capita healthcare expenditure increased significantly in Latin America. The healthcare expenditure in Latin America was around US$ 638 Mn in 2016, which increased to US$ 666 Mn by 2018.
Increasing approvals for product launches by the regulatory bodies is also expected to drive the market growth over the forecast period. For instance, in January 2019, Dacomitinib, a selective and irreversible inhibitor of EGFR by Pfizer Inc., a leading research-based biopharmaceutical company, received approval from the Ministry of Health, Labour and Welfare of Japan for the treatment of EGFR mutation-positive inoperable or recurrent non-small cell lung cancer (NSCLC).
Key features of the study:
This report provides in-depth analysis of the global dual specificity protein kinase TTK inhibitors market, market size (US$ Mn), and the compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dual specificity protein kinase TTK inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bayer AG, Pfizer Inc., Boston Pharmaceuticals, Nerviano Medical Sciences S.R.L (Part of NMS group), and Servier Laboratories
Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dual specificity protein kinase TTK inhibitors market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dual specificity protein kinase TTK inhibitors market
Detailed Segmentation:
Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Product Type:
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Application:
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Region:
North America
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
U.S.
Canada
Latin America
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Country
GCC
Israel
Rest of Middle East
Africa
Product Type
BAY 1217389
BOS-172722
CFI-402257
S 81694
Others
Application
Non-hematologic Malignancies
Breast Cancer
Prostate Cancer
Pancreatic Ductal Adenocarcinoma
Others
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Bayer AG
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Pfizer Inc.
Boston Pharmaceuticals
Nerviano Medical Sciences S.R.L (Part of NMS group)
Servier Laboratories.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
141 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Application
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- Mergers and Acquisitions
- Regulatory & Reimbursement Scenario
- 4. Global Dual Specificity Protein Kinase TTK Inhibitors Market – Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact on Healthcare Market
- New Developments
- Impact on Clinical Trials
- 5. Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Product Type, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- BAY 1217389
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- BOS-172722
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- CFI-402257
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- S 81694
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 6. Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Application, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Non-hematologic Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Pancreatic Ductal Adenocarcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 7. Global Dual Specificity Protein Kinase TTK Inhibitors Market, By Region, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2017 - 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2017 - 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- 8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boston Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Nerviano Medical Sciences S.R.L (Part of NMS group)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Servier Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
- 9. Section
- Research Methodology
- About us
- *Browse 26 market data tables and 26 figures on "Dual Specificity Protein Kinase TTK Inhibitors Market” - Global forecast to 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
